Cochlear (ASX: COH)‘s stock had its “underperform” rating restated by equities researchers at Credit Suisse in a report issued on Thursday. They currently have a $77.08 (74 AUD) target price on the stock.

Shares of Cochlear traded up 1.57% during mid-day trading on Thursday, hitting A$74.860. Cochlear has a 52 week low of A$51.310 and a 52 week high of A$71.790. The company has a market cap of A$4.257 billion and a P/E ratio of 73.85.

Other equities research analysts have also recently issued reports about the stock. Analysts at Goldman Sachs reiterated a “neutral” rating on shares of Cochlear in a research note to investors on Monday, November 12th. They now have a $67.71 price target on the stock. Analysts at Nomura reiterated a “neutral” rating on shares of Cochlear in a research note to investors on Tuesday, October 30th. They now have a $70.31 price target on the stock.

Cochlear Limited (Cochlear) is an Australia-based company, which operates in the implantable hearing device industry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.